درباره این اپیزود
Guest: James Taylor
In this episode of Boba & Biotech, Armon sits down with James Taylor, co-founder of Precision NanoSystems, for a candid conversation about building a platform technology for nanoparticle-delivered RNA medicines from a PhD project into an 11-year journey that ended in an acquisition by Danaher Corporation, a leading global life sciences and diagnostics healthcare company.
They cover the early grind of bootstrapping with non-dilutive grants, why it took five years to raise a Series A, and the case for staying a tools company even as the "sexier" path to therapeutics beckoned. Taylor opens up about a near-death experience scaling the sales team, the hard lessons of building a channel as a technical founder, and why boards don't run companies, management does. They also dig into building in Vancouver V.S. the US, the tension between royalty and per-unit business models, and what he'd change about how the industry communicates its impact to the world.
James Taylor is the Co-Founder and former CEO of Precision NanoSystems (PNI), a Vancouver-based life science tools company specializing in lipid nanoparticle platform technology. He holds a B.A.Sc. in engineering physics and a Ph.D. in genetics from the University of British Columbia (UBC). After 11 years building PNI, James led its acquisition by Danaher, where it was integrated into Cytiva's Life Sciences portfolio.
Links
-
Armon’s LinkedIn - https://www.linkedin.com/in/armonsharei/
-
James’ LinkedIn - https://www.linkedin.com/in/taylorrobertjames/
Credits
-
Hosted by Armon Sharei, PhD
-
Research by Julie Kim, MBA
-
Produced by David Woje, Woje Productions, Andressa Carroll, Portal
-
Edited and mixed by David Woje
